Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03762109 · ClinicalTrials.gov registry record · Phase 2
The Use of Dantrolene to Improve Analgesia in Posterior Lumbar Surgery
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
NCT03762109 is a Phase 2 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 116 participants.
The verdict
NCT03762109, a Phase 2 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether administration of a non-centrally acting muscle relaxants will improve the Overall Benefit of Analgesia Score (OBAS), and Richmond Agitation Sedation Scale (RASS) scores in patients undergoing lumbar fusion.
Interventions
- DRUG Dantrolene
- DRUG Placebo Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2019-07-29 |
| Est. Completion | 2024-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03762109
The ClinicalTrials.gov registry entry for NCT03762109 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dantrolene is the first listed.
NCT03762109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03762109 about?
NCT03762109 is a clinical study titled "The Use of Dantrolene to Improve Analgesia in Posterior Lumbar Surgery". The purpose of this study is to determine whether administration of a non-centrally acting muscle relaxants will improve the Overall Benefit of Analgesia Score (OBAS), and Richmond Agitation Sedation Scale (RASS) scores in patients undergoing lumbar fusion.
What is the current status of trial NCT03762109?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2019-07-29. Estimated completion is 2024-06-01.
What interventions are being tested in trial NCT03762109?
The interventions under investigation include: Dantrolene (DRUG), Placebo Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03762109?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.